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PROTEOLYTIC ACTIVITY IN DERMATOSES: STUDIES
OF BLOOD OF PATIENTS WITH PRURITUS*
FRANK E. CORMIA, M.D., JOHN W. DOUGHERTY, M.D. AND SHIRLEY UNRAU, B.A.
In a previous study, the role of proteolytic
enzymes in the production of itching was investi-
gated (1). Localized itching was produced
regularly by the intradermal injection of strep-
tokinase, profibrinolysin, fibrinolysin, and epi-
dermal protease. Itching could be produced also
by endopeptidases found in plants and animals,
for example, trypsin, ficin, and papain. In some
normal individuals, the intradermal injection
of streptokinase, human fibrinolysin, or bovine
crystalline trypsin was followed by scattered
itching lasting from one to eight hours. These
observations prompted measurements of proteo-
lytic activity of blood in normal controls and in
patients with severe itching. Additional observa-
tions were made before and after the intradermal
injection of bovine crystalline trypsin.
METHODS
Protease activity of plasma or serum was
estimated by measuring the hydrolysis of a syn-
thetic substrate: toluylsulfonyl-arginine-methyl
ester (TAME). On hydrolysis, the carboxylic
acid became free, displaced CO2 from the bicar-
bonate buffer and CO2 was measured mano-
metrically in a Warburg apparatus.
As a routine the enzyme containing globulin
fraction was precipitated out and the precipitate
dissolved in the original volume of saline. Two-
tenths (0.2) milliliters of globulin was incubated
for 60 minutes at 37° Centigrade with 20 micro-
moles of substrate. Activity of the enzyme was
expressed in terms of micromoles of enzyme
hydrolyzed per hour by 1 milliliter of plasma
(spontaneous plasmi n activity).
Antifibrinolytic activity was measured by add-
ing small concentrations of serum: 0.01 to 0.05
milliliters to 2 milligrams of bovine fibrinolysin
and measuring the decrease of activity of the
enzyme. Results were expressed as the amount of
enzyme activity supressed by 1 milliliter of serum
(as found by extrapolation).
Activator content was measured by adding 0.2
milliliters of plasma globulin to 0.05 milliliters of
a standard inactive and activator-free human
globulin. Activity above the added spontaneous
actions of the two components was considered due
to the activator present in the plasma sample and
expressed as above.
Solutions of crystalline trypsin* were freshly
prepared, the solvent being a specially prepared
buffered saline'. Five-hundreths (0.05) to 0.1
milliliter of a 1:1000 solution was then injected
intradermally.
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RESULTS
Normal subjects
Plasma fibrinolysin (protease) and serum
fibrinolysin inhibitor were measured in sixteen
subjects and plasma fibrinolysin activator in
eight of these. The range of fibrinolysin in units/
milliliters of plasma varied from 1.4 to 10.9
with an average of 5.76. The corresponding
serum inhibitor levels varied from 0.6 to 7.6
with an average of 3.22. The range of fibrinolysin
activator was 0 to 7.8 with an average of 4.1.
Patients with pruritus
Thirteen patients with various types of severe
pruritus were studied. The results are shown in
Table I.
In this group, fibrinolysin activator levels
varied from 0 to 7.8 units/milliliter with an
average of 2.6.
The plasma fibrinolysin levels varied from 5.1
to 8.7 with an average of 6.9 units/milliliter.
Serum fibrinolysin inhibitor levels varied from
0.5 to 5.4 units/milliliter with an average of
2.7.
Levels of plasma fibrinolysin activator, plasma
fibrinolysin and serum fibrinolysin inhibitor were
obtained before and two hours after the intrader-
mal injection of trypsin in eight subjects. Five of
these were normal controls, while the other three
were patients with severe scattered itching of
undetermined etiology. In three of the five
normal subjects, the injection of trypsin was
followed by Scattered itching beginning some
twenty minutes after injection and lasting from
two to four hours. This phenomenon was not
* Obtained from the Worthington Biochemical
Company, Freehold, New Jersey.
* From the Section on Dermatology, Department
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TABLE I
Proteolytic Activity in Blood of Patients
with Severe Prstritus
Diagnosis
Acti-
vator
Plasma
Plasma
Fibro-
inolysin
Serum
Inhi-
bitor
units! unils/ nnils/
ml. ml. ml.
1. diffuse neurodermatitis. . — 7.8 4.9
2. stasis eczema and neuro-
dermatitis 2.2 8.2 1.2
3. scattered pruritus, psy-
chogenic (?) 1.3 6.5 3.2
4. psychogenic itching 2.1 4.3 0.4
5. chronic pruritus, osteo-
porosis, arthritis 0 5.6 1.1
6. severe itching with gall
bladder disease 3.3 5.1 1.5
7. diabetes, cirrhosis with
jaundice, pruritus 2.4 6.5 1.9
8. erythroderma, lympho-
blastoma (?) 3.3 8.35 3.1
9. erythroderma, lympho-
blastoma (?) 0.45 6.7 3.4
10. severe itching, lympho-
blastoma (?) 0.2 8.7 5.4
11. Hodgkin's disease 5.2 7.6 3.1
12. Hodgkin's disease 0 2.4 0.8
13. pruritus, cancer (?) 7.8 5.1 0.5
noted in the other five subjects tested. Significant
deviations from the levels obtained in normal
controls were not found either before or after the
intradermal injection of trypsin.
COMMENT
A comparison of levels of plasma protease
activator, plasma protease (fibrinolysin), and
serum protease inhibitor in normal subjects and
in patients with severe, extensive pruritus did
not reveal significant differences. These findings
suggest that if proteolysis is responsible for
extensive pruritus, it may cccur primarily in
the skin. If the stimulus te protein breakdown
and pruritus is transported by the blood, it must
be present in a form not currently detectable.
In three subjects in whom scattered itching had
been produced by the intradermal injection of
trypsin, a comparison of pre- and post-trypsin
proteolytic activity in the blood did not show
significant variations. The experimental produc-
tion of scattered itching is apparently not due to
the activation of profibrinolysin by trypsin. It
is of interest that scattered itching could not be
produced by the intradermal injection of trypsin
in three patients with chronic intractable general-
ized pruritus. In these patients, the serum
fibrinolysin inhibitor was not elevated, and it is
postulated that failure to develop pruritus may
be due to an unknown host mechanism possibly
residing in the skin.
The possibility that increased proteolytic
activity of blood is related to extensive pruritus
could be neither confirmed nor disproved by the
present study.
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